期刊
BIOMOLECULES
卷 12, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/biom12111549
关键词
CD4 T cell; Eomesodermin; Th subsets; cytolytic CD4 T cell; Th1; Th17
资金
- NIH [R21AI146647, R21AI148882, R01AI167994]
CD4 T cells have both positive and negative impacts in infectious disease, cancer, autoimmunity, and allergy. They can differentiate into distinct effector subsets with specialized functions. Eomesodermin (Eomes) is an important transcription factor that may be targeted to improve clinical outcomes in CD4 T cell responses.
Central to the impacts of CD4 T cells, both positive in settings of infectious disease and cancer and negative in the settings of autoimmunity and allergy, is their ability to differentiate into distinct effector subsets with specialized functions. The programming required to support such responses is largely dictated by lineage-specifying transcription factors, often called 'master regulators'. However, it is increasingly clear that many aspects of CD4 T cell immunobiology that can determine the outcomes of disease states involve a broader transcriptional network. Eomesodermin (Eomes) is emerging as an important member of this class of transcription factors. While best studied in CD8 T cells and NK cells, an increasing body of work has focused on impacts of Eomes expression in CD4 T cell responses in an array of different settings. Here, we focus on the varied impacts reported in these studies that, together, indicate the potential of targeting Eomes expression in CD4 T cells as a strategy to improve a variety of clinical outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据